Antibody Drug Conjugates Market Size, Share & Trends Analysis Report By Application (Blood Cancer, Breast Cancer, Urothelial/Bladder Cancer), By Technology (Cleavable, Non-cleavable Linker, Linkerless), And Segment Forecasts, 2022 - 2030
This report can be delivered to the clients within 72 Business Hours
Antibody Drug Conjugates Market Growth & Trends
The global antibody drug conjugates market size is expected to reach over USD 22.87 billion by 2030, registering a CAGR of 16.4% during the forecast period, according to a new report by Grand View Research Inc. The presence of strong pipeline products and strategic initiatives undertaken by the key players are expected to drive the market growth during the forecast period.
Key players such as ADC Therapeutics, Seagen. Inc., Takeda Pharmaceutical Company Limited, F. Hoffmann-La Roche Ltd., AstraZeneca, Daiichi Sankyo, and others are collaborating to develop and commercialize products. For instance, in February 2022, Mersana Therapeutics, partnered with Janssen Pharmaceutical Companies, a subsidiary of Johnson & Johnson Inc., for the research and development of novel ADCs to treat various cancers. Under this agreement, Janssen will pay Mersana Therapeutics USD 40.0 million upfront and potentially more than USD 1.0 billion in milestone-based payments for the development of new ADCs.
Extensive research and rising funding for the development of novel antibody-drug conjugates by pharmaceutical companies is projected to drive market growth. For instance, in April 2021, Adcendo and Adcentrx, two new startups raised funding of around USD 112.0 million for the development of ADCs with their new approach to the treatment of cancer. Adcendo raised USD 51.0 million for the development of new ADCs that target endocytic receptors, which play the role of the drug delivery body. Adcentrx raised USD 50.0 million for its ADC research programs.
Stringent reimbursement policies for ADCs may restrain the market growth due to the high cost associated with the treatment of ADCs as compared to the alternative conventional treatments such as monoclonal antibodies therapy & chemotherapy. This higher cost of treatment is expected to impede reimbursement coverage. For instance, in February 2020, National Centre for Pharmaco economics, Ireland, gave a negative review for Roche’s Kadcyla (trastuzumab emtansine) for reimbursement consideration due to its low cost-effectiveness.
The rising geriatric population coupled with the increasing prevalence of the diseases such as multiple myeloma (MM) is expected to drive demand for ADCs, thereby driving the market growth during the forecast period. Multiple myeloma (MM) is a disease of the aging population, and nearly 30,000 new cases of MM were diagnosed in 2021. The median age of diagnosed patients with multiple myeloma is 70 years. Thus, the introduction of new ADCs for the treatment of multiple myeloma is expected to boost market growth. For instance, in August 2020, the FDA approved BLENREP by GlaxoSmithKline as a monotherapy to treat relapsed or refractory multiple myeloma. Blenrep was the first anti-BCMA therapy approved for the treatment of multiple myeloma.
Antibody drug Conjugates Market Report Highlights
Antibody Drug Conjugates Market Growth & Trends
The global antibody drug conjugates market size is expected to reach over USD 22.87 billion by 2030, registering a CAGR of 16.4% during the forecast period, according to a new report by Grand View Research Inc. The presence of strong pipeline products and strategic initiatives undertaken by the key players are expected to drive the market growth during the forecast period.
Key players such as ADC Therapeutics, Seagen. Inc., Takeda Pharmaceutical Company Limited, F. Hoffmann-La Roche Ltd., AstraZeneca, Daiichi Sankyo, and others are collaborating to develop and commercialize products. For instance, in February 2022, Mersana Therapeutics, partnered with Janssen Pharmaceutical Companies, a subsidiary of Johnson & Johnson Inc., for the research and development of novel ADCs to treat various cancers. Under this agreement, Janssen will pay Mersana Therapeutics USD 40.0 million upfront and potentially more than USD 1.0 billion in milestone-based payments for the development of new ADCs.
Extensive research and rising funding for the development of novel antibody-drug conjugates by pharmaceutical companies is projected to drive market growth. For instance, in April 2021, Adcendo and Adcentrx, two new startups raised funding of around USD 112.0 million for the development of ADCs with their new approach to the treatment of cancer. Adcendo raised USD 51.0 million for the development of new ADCs that target endocytic receptors, which play the role of the drug delivery body. Adcentrx raised USD 50.0 million for its ADC research programs.
Stringent reimbursement policies for ADCs may restrain the market growth due to the high cost associated with the treatment of ADCs as compared to the alternative conventional treatments such as monoclonal antibodies therapy & chemotherapy. This higher cost of treatment is expected to impede reimbursement coverage. For instance, in February 2020, National Centre for Pharmaco economics, Ireland, gave a negative review for Roche’s Kadcyla (trastuzumab emtansine) for reimbursement consideration due to its low cost-effectiveness.
The rising geriatric population coupled with the increasing prevalence of the diseases such as multiple myeloma (MM) is expected to drive demand for ADCs, thereby driving the market growth during the forecast period. Multiple myeloma (MM) is a disease of the aging population, and nearly 30,000 new cases of MM were diagnosed in 2021. The median age of diagnosed patients with multiple myeloma is 70 years. Thus, the introduction of new ADCs for the treatment of multiple myeloma is expected to boost market growth. For instance, in August 2020, the FDA approved BLENREP by GlaxoSmithKline as a monotherapy to treat relapsed or refractory multiple myeloma. Blenrep was the first anti-BCMA therapy approved for the treatment of multiple myeloma.
Antibody drug Conjugates Market Report Highlights
- Breast cancer dominated the market in 2021, owing to the high prevalence of breast cancer and the availability of multiple ADC products for treating the breast cancer
- Cleavable linker segment dominated the market in 2021 due to the rising adoption of cleavable linker technology in commercial ADC products and the advantages associated with the use of cleavable linkers over other linker technology
- North America dominated the market in 2021 due to the presence of key pharmaceutical companies such as Pfizer, Inc, Gilead Life Sciences, Inc., and Seagen, Inc. and their strategic initiatives for the development of new ADCs
CHAPTER 1. METHODOLOGY AND SCOPE
1.1 Market Segmentation And Scope
1.1.1 Segment Scope
1.1.2 Regional Scope
1.1.3 Estimates And Forecast Timeline
1.2 Research Methodology
1.3 Information Procurement
1.3.1 Purchased Database
1.3.2 Gvr’s Internal Database
1.3.3 Secondary Sources
1.3.4 Primary Research
1.3.5 Details Of Primary Research
1.4 Information Or Data Analysis
1.4.1 Data Analysis Models
1.5 Market Formulation & Validation
1.6 Model Details
1.6.1 Commodity Flow Analysis
1.6.1.1 Approach 1: Commodity Flow Approach
1.6.1.2 Approach 2: Country Wise Market Estimation Using Bottom-Up Approach
1.7 Global Market: Cagr Calculation
1.8 Research Assumptions
1.9 List Of Secondary Sources
1.10 List Of Primary Sources
1.11 Objectives
1.12 List Of Abbreviations
CHAPTER 2. EXECUTIVE SUMMARIES
2.1 Market Summary
CHAPTER 3. INDUSTRY OUTLOOKS
3.1 Market Variable Analysis
3.2 Driver Impact Analysis
3.2.1 Presence Of Strong Product Pipeline
3.2.2 Growing Geriatric Population Base
3.2.3 Increasing Incidence And Prevalence Of Cancer
3.3 Market Restraint Analysis
3.3.1 High Manufacturing Cost And Downstream Processing Challenges For Adcs
3.3.2 Stringent Reimbursement Policies For Adcs
3.4 Penetration And Growth Prospect Mapping
3.5 Swot Analysis; By Factor (Political & Legal, Economic And Technological)
3.6 Porter’s Five Forces Analysis
3.7 Pipeline Analysis
CHAPTER 4. APPLICATION BUSINESS ANALYSIS
4.1 Antibody-Drug Conjugates Market: Application Movement Analysis
4.2 Blood Cancer
4.2.1 Blood Cancer Market Estimates And Forecast 2017 - 2030
4.2.2 Leukemia
4.2.2.1 Leukemia Market Estimates And Forecast 2017 - 2030
4.2.3 Multiple Myeloma
4.2.3.1 Multiple Myeloma Market Estimates And Forecast 2017 - 2030
4.2.4 Lymphoma
4.2.4.1 Lymphoma Market Estimates And Forecast 2017 - 2030
4.3 Breast Cancer
4.3.1 Breast Cancer Market Estimates And Forecast 2017 - 2030
4.4 Urothelial/Bladder Cancer
4.4.1 Urothelial/Bladder Cancer Market Estimates And Forecast 2017 - 2030
4.5 Others
4.5.1 Others Market Estimates And Forecast 2017 - 2030
CHAPTER 5. TECHNOLOGY BUSINESS ANALYSIS
5.1 Antibody-Drug Conjugates Market: Technology Movement Analysis
5.2 Cleavable Linker
5.2.1 Cleavable Linker Market Estimates And Forecast 2017 - 2030
5.3 Non-Cleavable Linker
5.3.1 Non-Cleavable Linker Market Estimates And Forecast 2017 - 2030
5.4 Linker Less
5.4.1 Linkerless Market Estimates And Forecast 2017 - 2030
CHAPTER 6. REGIONAL BUSINESS ANALYSES
6.1 Antibody-Drug Conjugates Market: Regional Movement Analysis
6.2 North America
6.2.1 North America Market Estimates And Forecast 2017 - 2030 (USD Million)
6.2.2 U.S.
6.2.2.1 U.S. Market Estimates And Forecast 2017 - 2030 (USD Million)
6.2.3 Canada
6.2.3.1 Canada Market Estimates And Forecast 2017 - 2030 (USD Million)
6.3 Europe
6.3.1 Europe Market Estimates And Forecast 2017 - 2030 (USD Million)
6.3.2 Uk
6.3.2.1 Uk Market Estimates And Forecast 2017 - 2030 (USD Million)
6.3.3 Germany
6.3.3.1 Germany Market Estimates And Forecast 2017 - 2030 (USD Million)
6.3.4 Italy
6.3.4.1 Italy Market Estimates And Forecast 2017 - 2030 (USD Million)
6.3.5 Spain
6.3.5.1 Spain Market Estimates And Forecast 2017 - 2030 (USD Million)
6.3.6 France
6.3.6.1 France Market Estimates And Forecast 2017 - 2030 (USD Million)
6.3.7 Russia
6.3.6.1 Russia Market Estimates And Forecast 2017 - 2030 (USD Million)
6.4 Asia Pacific
6.4.1 Asia Pacific Market Estimates And Forecast 2017 - 2030 (USD Million)
6.4.2 Japan
6.4.2.1 Japan Market Estimates And Forecast 2017 - 2030 (USD Million)
6.4.3 China
6.4.3.1 China Market Estimates And Forecast 2017 - 2030 (USD Million)
6.4.4 India
6.4.4.1 India Market Estimates And Forecast 2017 - 2030 (USD Million)
6.4.5 Australia
6.4.5.1 Australia Market Estimates And Forecast 2017 - 2030 (USD Million)
6.4.6 South Korea
6.4.6.1 South Korea Market Estimates And Forecast 2017 - 2030 (USD Million)
6.4.7 Singapore
6.4.7.1 Singapore Market Estimates And Forecast 2017 - 2030 (USD Million)
6.5 Latin America
6.5.1 Latin America Market Estimates And Forecast 2017 - 2030 (USD Million)
6.5.2 Brazil
6.5.2.1 Brazil Market Estimates And Forecast 2017 - 2030 (USD Million)
6.5.3 Mexico
6.5.3.1 Mexico Market Estimates And Forecast 2017 - 2030 (USD Million)
6.5.4 Argentina
6.5.4.1 Argentina Market Estimates And Forecast 2017 - 2030 (USD Million)
6.6 Middle East & Africa
6.6.1 Middle-East And Africa Market Estimates And Forecast 2017 - 2030 (USD Million)
6.6.2 South Africa
6.6.2.1 South Africa Market Estimates And Forecast 2017 - 2030 (USD Million)
6.6.3 Saudi Arabia
6.6.3.1 Saudi Arabia Market Estimates And Forecast 2017 - 2030 (USD Million)
6.6.4 Uae
6.6.4.1 Uae Market Estimates And Forecast 2017 - 2030 (USD Million)
CHAPTER 7. COMPETITIVE LANDSCAPE
7.1 Major Deals & Strategic Alliances Analysis
7.1.1 New Product Launch
7.1.2 Mergers And Acquisitions
7.1.3 Expansion
7.1.4 Partnerships
7.2 Vendor Landscape
7.2.1 List Of Key Distributors And Channel Partners
7.2.2 Key Company Market Share Analysis, 2020
7.3 Public Companies
7.3.1 Company Market Position Analysis
7.3.2 Competitive Dashboard Analysis
7.4 Private Companies
7.4.1 List Of Key Emerging Companies/Technology Disruptors/ Innovators
CHAPTER 8. COMPANY PROFILES
8.1 Takeda Pharmaceutical Company Limited
8.1.1 Company Overview
8.1.2 Financial Performance
8.1.3 Product Benchmarking
8.1.4 Strategic Initiatives
8.2 F. Hoffmann-La Roche Ltd.
8.2.1 Company Overview
8.2.2 Financial Performance
8.2.3 Product Benchmarking
8.2.4 Strategic Initiatives
8.3 Pfizer, Inc.
8.3.1 Company Overview
8.3.2 Financial Performance
8.3.3 Product Benchmarking
8.3.4 Strategic Initiatives
8.4 Astrazeneca
8.4.1 Company Overview
8.4.2 Financial Performance
8.4.3 Product Benchmarking
8.4.4 Strategic Initiatives
8.5 Gilead Sciences, Inc.
8.5.1 Company Overview
8.5.2 Financial Performance
8.5.3 Product Benchmarking
8.5.4 Strategic Initiatives
8.6 Astellas Pharma, Inc.
8.6.1 Company Overview
8.6.2 Financial Performance
8.6.3 Product Benchmarking
8.6.4 Strategic Initiatives
8.7 Seagen, Inc.
8.7.1 Company Overview
8.7.2 Financial Performance
8.7.3 Product Benchmarking
8.7.4 Strategic Initiatives
8.8 Daiichi Sankyo Company, Limited
8.8.1 Company Overview
8.8.2 Financial Performance
8.8.3 Product Benchmarking
8.8.4 Strategic Initiatives
8.9 Glaxosmithkline Plc
8.9.1 Company Overview
8.9.2 Financial Performance
8.9.3 Product Benchmarking
8.9.4 Strategic Initiatives
8.10 ADC Therapeutics SAa
8.10.1 Company Overview
8.10.2 Financial Performance
8.10.3 Product Benchmarking
8.10.4 Strategic Initiatives
1.1 Market Segmentation And Scope
1.1.1 Segment Scope
1.1.2 Regional Scope
1.1.3 Estimates And Forecast Timeline
1.2 Research Methodology
1.3 Information Procurement
1.3.1 Purchased Database
1.3.2 Gvr’s Internal Database
1.3.3 Secondary Sources
1.3.4 Primary Research
1.3.5 Details Of Primary Research
1.4 Information Or Data Analysis
1.4.1 Data Analysis Models
1.5 Market Formulation & Validation
1.6 Model Details
1.6.1 Commodity Flow Analysis
1.6.1.1 Approach 1: Commodity Flow Approach
1.6.1.2 Approach 2: Country Wise Market Estimation Using Bottom-Up Approach
1.7 Global Market: Cagr Calculation
1.8 Research Assumptions
1.9 List Of Secondary Sources
1.10 List Of Primary Sources
1.11 Objectives
1.12 List Of Abbreviations
CHAPTER 2. EXECUTIVE SUMMARIES
2.1 Market Summary
CHAPTER 3. INDUSTRY OUTLOOKS
3.1 Market Variable Analysis
3.2 Driver Impact Analysis
3.2.1 Presence Of Strong Product Pipeline
3.2.2 Growing Geriatric Population Base
3.2.3 Increasing Incidence And Prevalence Of Cancer
3.3 Market Restraint Analysis
3.3.1 High Manufacturing Cost And Downstream Processing Challenges For Adcs
3.3.2 Stringent Reimbursement Policies For Adcs
3.4 Penetration And Growth Prospect Mapping
3.5 Swot Analysis; By Factor (Political & Legal, Economic And Technological)
3.6 Porter’s Five Forces Analysis
3.7 Pipeline Analysis
CHAPTER 4. APPLICATION BUSINESS ANALYSIS
4.1 Antibody-Drug Conjugates Market: Application Movement Analysis
4.2 Blood Cancer
4.2.1 Blood Cancer Market Estimates And Forecast 2017 - 2030
4.2.2 Leukemia
4.2.2.1 Leukemia Market Estimates And Forecast 2017 - 2030
4.2.3 Multiple Myeloma
4.2.3.1 Multiple Myeloma Market Estimates And Forecast 2017 - 2030
4.2.4 Lymphoma
4.2.4.1 Lymphoma Market Estimates And Forecast 2017 - 2030
4.3 Breast Cancer
4.3.1 Breast Cancer Market Estimates And Forecast 2017 - 2030
4.4 Urothelial/Bladder Cancer
4.4.1 Urothelial/Bladder Cancer Market Estimates And Forecast 2017 - 2030
4.5 Others
4.5.1 Others Market Estimates And Forecast 2017 - 2030
CHAPTER 5. TECHNOLOGY BUSINESS ANALYSIS
5.1 Antibody-Drug Conjugates Market: Technology Movement Analysis
5.2 Cleavable Linker
5.2.1 Cleavable Linker Market Estimates And Forecast 2017 - 2030
5.3 Non-Cleavable Linker
5.3.1 Non-Cleavable Linker Market Estimates And Forecast 2017 - 2030
5.4 Linker Less
5.4.1 Linkerless Market Estimates And Forecast 2017 - 2030
CHAPTER 6. REGIONAL BUSINESS ANALYSES
6.1 Antibody-Drug Conjugates Market: Regional Movement Analysis
6.2 North America
6.2.1 North America Market Estimates And Forecast 2017 - 2030 (USD Million)
6.2.2 U.S.
6.2.2.1 U.S. Market Estimates And Forecast 2017 - 2030 (USD Million)
6.2.3 Canada
6.2.3.1 Canada Market Estimates And Forecast 2017 - 2030 (USD Million)
6.3 Europe
6.3.1 Europe Market Estimates And Forecast 2017 - 2030 (USD Million)
6.3.2 Uk
6.3.2.1 Uk Market Estimates And Forecast 2017 - 2030 (USD Million)
6.3.3 Germany
6.3.3.1 Germany Market Estimates And Forecast 2017 - 2030 (USD Million)
6.3.4 Italy
6.3.4.1 Italy Market Estimates And Forecast 2017 - 2030 (USD Million)
6.3.5 Spain
6.3.5.1 Spain Market Estimates And Forecast 2017 - 2030 (USD Million)
6.3.6 France
6.3.6.1 France Market Estimates And Forecast 2017 - 2030 (USD Million)
6.3.7 Russia
6.3.6.1 Russia Market Estimates And Forecast 2017 - 2030 (USD Million)
6.4 Asia Pacific
6.4.1 Asia Pacific Market Estimates And Forecast 2017 - 2030 (USD Million)
6.4.2 Japan
6.4.2.1 Japan Market Estimates And Forecast 2017 - 2030 (USD Million)
6.4.3 China
6.4.3.1 China Market Estimates And Forecast 2017 - 2030 (USD Million)
6.4.4 India
6.4.4.1 India Market Estimates And Forecast 2017 - 2030 (USD Million)
6.4.5 Australia
6.4.5.1 Australia Market Estimates And Forecast 2017 - 2030 (USD Million)
6.4.6 South Korea
6.4.6.1 South Korea Market Estimates And Forecast 2017 - 2030 (USD Million)
6.4.7 Singapore
6.4.7.1 Singapore Market Estimates And Forecast 2017 - 2030 (USD Million)
6.5 Latin America
6.5.1 Latin America Market Estimates And Forecast 2017 - 2030 (USD Million)
6.5.2 Brazil
6.5.2.1 Brazil Market Estimates And Forecast 2017 - 2030 (USD Million)
6.5.3 Mexico
6.5.3.1 Mexico Market Estimates And Forecast 2017 - 2030 (USD Million)
6.5.4 Argentina
6.5.4.1 Argentina Market Estimates And Forecast 2017 - 2030 (USD Million)
6.6 Middle East & Africa
6.6.1 Middle-East And Africa Market Estimates And Forecast 2017 - 2030 (USD Million)
6.6.2 South Africa
6.6.2.1 South Africa Market Estimates And Forecast 2017 - 2030 (USD Million)
6.6.3 Saudi Arabia
6.6.3.1 Saudi Arabia Market Estimates And Forecast 2017 - 2030 (USD Million)
6.6.4 Uae
6.6.4.1 Uae Market Estimates And Forecast 2017 - 2030 (USD Million)
CHAPTER 7. COMPETITIVE LANDSCAPE
7.1 Major Deals & Strategic Alliances Analysis
7.1.1 New Product Launch
7.1.2 Mergers And Acquisitions
7.1.3 Expansion
7.1.4 Partnerships
7.2 Vendor Landscape
7.2.1 List Of Key Distributors And Channel Partners
7.2.2 Key Company Market Share Analysis, 2020
7.3 Public Companies
7.3.1 Company Market Position Analysis
7.3.2 Competitive Dashboard Analysis
7.4 Private Companies
7.4.1 List Of Key Emerging Companies/Technology Disruptors/ Innovators
CHAPTER 8. COMPANY PROFILES
8.1 Takeda Pharmaceutical Company Limited
8.1.1 Company Overview
8.1.2 Financial Performance
8.1.3 Product Benchmarking
8.1.4 Strategic Initiatives
8.2 F. Hoffmann-La Roche Ltd.
8.2.1 Company Overview
8.2.2 Financial Performance
8.2.3 Product Benchmarking
8.2.4 Strategic Initiatives
8.3 Pfizer, Inc.
8.3.1 Company Overview
8.3.2 Financial Performance
8.3.3 Product Benchmarking
8.3.4 Strategic Initiatives
8.4 Astrazeneca
8.4.1 Company Overview
8.4.2 Financial Performance
8.4.3 Product Benchmarking
8.4.4 Strategic Initiatives
8.5 Gilead Sciences, Inc.
8.5.1 Company Overview
8.5.2 Financial Performance
8.5.3 Product Benchmarking
8.5.4 Strategic Initiatives
8.6 Astellas Pharma, Inc.
8.6.1 Company Overview
8.6.2 Financial Performance
8.6.3 Product Benchmarking
8.6.4 Strategic Initiatives
8.7 Seagen, Inc.
8.7.1 Company Overview
8.7.2 Financial Performance
8.7.3 Product Benchmarking
8.7.4 Strategic Initiatives
8.8 Daiichi Sankyo Company, Limited
8.8.1 Company Overview
8.8.2 Financial Performance
8.8.3 Product Benchmarking
8.8.4 Strategic Initiatives
8.9 Glaxosmithkline Plc
8.9.1 Company Overview
8.9.2 Financial Performance
8.9.3 Product Benchmarking
8.9.4 Strategic Initiatives
8.10 ADC Therapeutics SAa
8.10.1 Company Overview
8.10.2 Financial Performance
8.10.3 Product Benchmarking
8.10.4 Strategic Initiatives
LIST OF TABLES
TABLE 1 List of secondary sources
TABLE 2 List of Abbreviations
TABLE 3 North America antibody-drug conjugates market estimates and forecasts, by application 2017 - 2030 (USD Million)
TABLE 4 North America antibody-drug conjugates market estimates and forecasts, by technology 2017 - 2030 (USD Million)
TABLE 5 U.S. antibody-drug conjugates market estimates and forecasts, by application 2017 - 2030 (USD Million)
TABLE 6 U.S. antibody-drug conjugates market estimates and forecasts, by technology 2017 - 2030 (USD Million)
TABLE 7 Canada antibody-drug conjugates market estimates and forecasts, by application 2017 - 2030 (USD Million)
TABLE 8 Canada antibody-drug conjugates market estimates and forecasts, by technology 2017 - 2030 (USD Million)
TABLE 9 Europe antibody-drug conjugates market estimates and forecasts, by application 2017 - 2030 (USD Million)
TABLE 10 Europe antibody-drug conjugates market estimates and forecasts, by technology 2017 - 2030 (USD Million)
TABLE 11 U.K. antibody-drug conjugates market estimates and forecasts, by application, 2017 - 62028 (USD Million)
TABLE 12 U.K. antibody-drug conjugates market estimates and forecasts, by technology 2017 - 2030 (USD Million)
TABLE 13 Germany antibody-drug conjugates market estimates and forecasts, by application 2017 - 2030 (USD Million)
TABLE 14 Germany antibody-drug conjugates market estimates and forecasts, by technology 2017 - 2030 (USD Million)
TABLE 15 France antibody-drug conjugates market estimates and forecasts, by application 2017 - 2030 (USD Million)
TABLE 16 France antibody-drug conjugates market estimates and forecasts, by technology 2017 - 2030 (USD Million)
TABLE 17 Italy antibody-drug conjugates market estimates and forecasts, by application 2017 - 2030 (USD Million)
TABLE 18 Italy antibody-drug conjugates market estimates and forecasts, by technology 2017 - 2030 (USD Million)
TABLE 19 Spainantibody-drug conjugates market estimates and forecasts, by application 2017 - 2030 (USD Million)
TABLE 20 Spain antibody-drug conjugates market estimates and forecasts, by technology 2017 - 2030 (USD Million)
TABLE 21 Russiaantibody-drug conjugates market estimates and forecasts, by application 2017 - 2030 (USD Million)
TABLE 22 Russia antibody-drug conjugates market estimates and forecasts, by technology 2017 - 2030 (USD Million)
TABLE 23 Asia Pacific antibody-drug conjugates market estimates and forecasts, by application 2017 - 2030 (USD Million)
TABLE 24 Asia Pacific antibody-drug conjugates market estimates and forecasts, by technology 2017 - 2030 (USD Million)
TABLE 25 Japan antibody-drug conjugates market estimates and forecasts, by application 2017 - 2030 (USD Million)
TABLE 26 Japan antibody-drug conjugates market estimates and forecasts, by technology 2017 - 2030 (USD Million)
TABLE 27 China antibody-drug conjugates market estimates and forecasts, by application 2017 - 2030 (USD Million)
TABLE 28 China antibody-drug conjugates market estimates and forecasts, by technology 2017 - 2030 (USD Million)
TABLE 29 India antibody-drug conjugates market estimates and forecasts, by application 2017 - 2030 (USD Million)
TABLE 30 India antibody-drug conjugates market estimates and forecasts, by technology 2017 - 2030 (USD Million)
TABLE 31 Australia antibody-drug conjugates market estimates and forecasts, by application 2017 - 2030 (USD Million)
TABLE 32 Australia antibody-drug conjugates market estimates and forecasts, by technology 2017 - 2030 (USD Million)
TABLE 33 South Korea antibody-drug conjugates market estimates and forecasts, by application 2017 - 2030 (USD Million)
TABLE 34 South Korea antibody-drug conjugates market estimates and forecasts, by technology 2017 - 2030 (USD Million)
TABLE 35 Singapore antibody-drug conjugates market estimates and forecasts, by application 2017 - 2030 (USD Million)
TABLE 36 Singapore antibody-drug conjugates market estimates and forecasts, by technology 2017 - 2030 (USD Million)
TABLE 37 Latin America antibody-drug conjugates market estimates and forecasts, by application 2017 - 2030 (USD Million)
TABLE 38 Latin America antibody-drug conjugates market estimates and forecasts, by technology 2017 - 2030 (USD Million)
TABLE 39 Brazil antibody-drug conjugates market estimates and forecasts, by application 2017 - 2030 (USD Million)
TABLE 40 Brazil antibody-drug conjugates market estimates and forecasts, by technology 2017 - 2030 (USD Million)
TABLE 41 Mexico antibody-drug conjugates market estimates and forecasts, by application 2017 - 2030 (USD Million)
TABLE 42 Mexico antibody-drug conjugates market estimates and forecasts, by technology 2017 - 2030 (USD Million)
TABLE 43 Argentina antibody-drug conjugates market estimates and forecasts, by application 2017 - 2030 (USD Million)
TABLE 44 Argentina antibody-drug conjugates market estimates and forecasts, by technology 2017 - 2030 (USD Million)
TABLE 45 MEA antibody-drug conjugates market estimates and forecasts, by application 2017 - 2030 (USD Million)
TABLE 46 MEA antibody-drug conjugates market estimates and forecasts, by technology 2017 - 2030 (USD Million)
TABLE 47 South Africa antibody-drug conjugates market estimates and forecasts, by application 2017 - 2030 (USD Million)
TABLE 48 South Africa antibody-drug conjugates market estimates and forecasts, by technology 2017 - 2030 (USD Million)
TABLE 49Saudi Arabiaantibody-drug conjugates market estimates and forecasts, by application 2017 - 2030 (USD Million)
TABLE 50 Saudi Arabia antibody-drug conjugates market estimates and forecasts, by technology 2017 - 2030 (USD Million)
TABLE 51 UAE antibody-drug conjugates market estimates and forecasts, by application 2017 - 2030 (USD Million)
TABLE 52 UAE antibody-drug conjugates market estimates and forecasts, by technology 2017 - 2030 (USD Million)
Table 53 List of key distributors
Table 54 List of key emerging companies/technology disruptors/innovators
TABLE 1 List of secondary sources
TABLE 2 List of Abbreviations
TABLE 3 North America antibody-drug conjugates market estimates and forecasts, by application 2017 - 2030 (USD Million)
TABLE 4 North America antibody-drug conjugates market estimates and forecasts, by technology 2017 - 2030 (USD Million)
TABLE 5 U.S. antibody-drug conjugates market estimates and forecasts, by application 2017 - 2030 (USD Million)
TABLE 6 U.S. antibody-drug conjugates market estimates and forecasts, by technology 2017 - 2030 (USD Million)
TABLE 7 Canada antibody-drug conjugates market estimates and forecasts, by application 2017 - 2030 (USD Million)
TABLE 8 Canada antibody-drug conjugates market estimates and forecasts, by technology 2017 - 2030 (USD Million)
TABLE 9 Europe antibody-drug conjugates market estimates and forecasts, by application 2017 - 2030 (USD Million)
TABLE 10 Europe antibody-drug conjugates market estimates and forecasts, by technology 2017 - 2030 (USD Million)
TABLE 11 U.K. antibody-drug conjugates market estimates and forecasts, by application, 2017 - 62028 (USD Million)
TABLE 12 U.K. antibody-drug conjugates market estimates and forecasts, by technology 2017 - 2030 (USD Million)
TABLE 13 Germany antibody-drug conjugates market estimates and forecasts, by application 2017 - 2030 (USD Million)
TABLE 14 Germany antibody-drug conjugates market estimates and forecasts, by technology 2017 - 2030 (USD Million)
TABLE 15 France antibody-drug conjugates market estimates and forecasts, by application 2017 - 2030 (USD Million)
TABLE 16 France antibody-drug conjugates market estimates and forecasts, by technology 2017 - 2030 (USD Million)
TABLE 17 Italy antibody-drug conjugates market estimates and forecasts, by application 2017 - 2030 (USD Million)
TABLE 18 Italy antibody-drug conjugates market estimates and forecasts, by technology 2017 - 2030 (USD Million)
TABLE 19 Spainantibody-drug conjugates market estimates and forecasts, by application 2017 - 2030 (USD Million)
TABLE 20 Spain antibody-drug conjugates market estimates and forecasts, by technology 2017 - 2030 (USD Million)
TABLE 21 Russiaantibody-drug conjugates market estimates and forecasts, by application 2017 - 2030 (USD Million)
TABLE 22 Russia antibody-drug conjugates market estimates and forecasts, by technology 2017 - 2030 (USD Million)
TABLE 23 Asia Pacific antibody-drug conjugates market estimates and forecasts, by application 2017 - 2030 (USD Million)
TABLE 24 Asia Pacific antibody-drug conjugates market estimates and forecasts, by technology 2017 - 2030 (USD Million)
TABLE 25 Japan antibody-drug conjugates market estimates and forecasts, by application 2017 - 2030 (USD Million)
TABLE 26 Japan antibody-drug conjugates market estimates and forecasts, by technology 2017 - 2030 (USD Million)
TABLE 27 China antibody-drug conjugates market estimates and forecasts, by application 2017 - 2030 (USD Million)
TABLE 28 China antibody-drug conjugates market estimates and forecasts, by technology 2017 - 2030 (USD Million)
TABLE 29 India antibody-drug conjugates market estimates and forecasts, by application 2017 - 2030 (USD Million)
TABLE 30 India antibody-drug conjugates market estimates and forecasts, by technology 2017 - 2030 (USD Million)
TABLE 31 Australia antibody-drug conjugates market estimates and forecasts, by application 2017 - 2030 (USD Million)
TABLE 32 Australia antibody-drug conjugates market estimates and forecasts, by technology 2017 - 2030 (USD Million)
TABLE 33 South Korea antibody-drug conjugates market estimates and forecasts, by application 2017 - 2030 (USD Million)
TABLE 34 South Korea antibody-drug conjugates market estimates and forecasts, by technology 2017 - 2030 (USD Million)
TABLE 35 Singapore antibody-drug conjugates market estimates and forecasts, by application 2017 - 2030 (USD Million)
TABLE 36 Singapore antibody-drug conjugates market estimates and forecasts, by technology 2017 - 2030 (USD Million)
TABLE 37 Latin America antibody-drug conjugates market estimates and forecasts, by application 2017 - 2030 (USD Million)
TABLE 38 Latin America antibody-drug conjugates market estimates and forecasts, by technology 2017 - 2030 (USD Million)
TABLE 39 Brazil antibody-drug conjugates market estimates and forecasts, by application 2017 - 2030 (USD Million)
TABLE 40 Brazil antibody-drug conjugates market estimates and forecasts, by technology 2017 - 2030 (USD Million)
TABLE 41 Mexico antibody-drug conjugates market estimates and forecasts, by application 2017 - 2030 (USD Million)
TABLE 42 Mexico antibody-drug conjugates market estimates and forecasts, by technology 2017 - 2030 (USD Million)
TABLE 43 Argentina antibody-drug conjugates market estimates and forecasts, by application 2017 - 2030 (USD Million)
TABLE 44 Argentina antibody-drug conjugates market estimates and forecasts, by technology 2017 - 2030 (USD Million)
TABLE 45 MEA antibody-drug conjugates market estimates and forecasts, by application 2017 - 2030 (USD Million)
TABLE 46 MEA antibody-drug conjugates market estimates and forecasts, by technology 2017 - 2030 (USD Million)
TABLE 47 South Africa antibody-drug conjugates market estimates and forecasts, by application 2017 - 2030 (USD Million)
TABLE 48 South Africa antibody-drug conjugates market estimates and forecasts, by technology 2017 - 2030 (USD Million)
TABLE 49Saudi Arabiaantibody-drug conjugates market estimates and forecasts, by application 2017 - 2030 (USD Million)
TABLE 50 Saudi Arabia antibody-drug conjugates market estimates and forecasts, by technology 2017 - 2030 (USD Million)
TABLE 51 UAE antibody-drug conjugates market estimates and forecasts, by application 2017 - 2030 (USD Million)
TABLE 52 UAE antibody-drug conjugates market estimates and forecasts, by technology 2017 - 2030 (USD Million)
Table 53 List of key distributors
Table 54 List of key emerging companies/technology disruptors/innovators
LIST OF FIGURES
Fig. 1 Antibody-drug conjugates market segmentation
Fig. 2 Market research process
Fig. 3 Data triangulation techniques
Fig. 4 Primary research pattern
Fig. 5 Market research approaches
Fig. 6 Value-chain-based sizing & forecasting
Fig. 7 QFD modeling for market share assessment
Fig. 8 Market formulation & validation
Fig. 9 Antibody-drug conjugates market snapshot
Fig. 10 Antibody-drug conjugates market driver impact
Fig. 11 Global population by age group, 2016, 2020, & 2027
Fig. 12 Global cancer cases projection,2020 - 2030 (Number of new registered cases)
Fig. 13 Antibody-drug conjugates market restraint impact
Fig. 14 Penetration and growth prospect mapping
Fig. 15 SWOT analysis, by factor (political & legal economic and technological)
Fig. 16 Porter’s five forces analysis
Fig. 17 Antibody-drug conjugates market: Application outlook and key takeaways
Fig. 18 Antibody-drug conjugates market: Application movement analysis
Fig. 19 Blood cancer market estimates and forecasts, 2017 - 2030
Fig. 20 Leukemia market estimates and forecasts, 2017 - 2030
Fig. 21 Multiple Myeloma market estimates and forecasts, 2017 - 2030
Fig. 22 Lymphoma market estimates and forecasts, 2017 - 2030
Fig. 23 Breast cancer market estimates and forecasts, 2017 - 2030
Fig. 24 Urothelial cancer market estimates and forecasts, 2017 - 2030
Fig. 25 Others market estimates and forecasts, 2017 - 2030
Fig. 26 Antibody-drug conjugates market: Technology outlook and key takeaways
Fig. 27 Antibody-drug conjugates market: Technology movement analysis
Fig. 28 Cleavable linker market estimates and forecasts, 2017 - 2030
Fig. 29 Non-cleavable linker market estimates and forecasts, 2017 - 2030
Fig. 30 Linkerless market estimates and forecasts, 2017 - 2030
Fig. 31 Antibody-drug conjugates market: Regional outlook and key takeaways
Fig. 32 Antibody-drug conjugates market: Regional movement analysis
Fig. 33 North America
Fig. 34 North America market estimates and forecast 2017 - 2030 (USD Million)
Fig. 35 U.S.
Fig. 36 U.S. market estimates and forecast 2017 - 2030 (USD Million)
Fig. 37 Canada
Fig. 38 Canada market estimates and forecast 2017 - 2030 (USD Million)
Fig. 39 Europe
Fig. 40 Europe market estimates and forecast 2017 - 2030 (USD Million)
Fig. 41 UK
Fig. 42 UK market estimates and forecast 2017 - 2030 (USD Million)
Fig. 43 Germany
Fig. 44 Germany market estimates and forecast 2017 - 2030 (USD Million)
Fig. 45 Italy
Fig. 46 Italy market estimates and forecast 2017 - 2030 (USD Million)
Fig. 47 Spain
Fig. 48 Spain market estimates and forecast 2017 - 2030 (USD Million)
Fig. 49 Russia
Fig. 50 Russia market estimates and forecast 2017 - 2030 (USD Million)
Fig. 51 France
Fig. 52 France market estimates and forecast 2017 - 2030 (USD Million)
Fig. 53 Asia Pacific
Fig. 54 Asia Pacific market estimates and forecast 2017 - 2030 (USD Million)
Fig. 55 Japan
Fig. 56 Japan market estimates and forecast 2017 - 2030 (USD Million)
Fig. 57 China
Fig. 58 China market estimates and forecast 2017 - 2030 (USD Million)
Fig. 59 India
Fig. 60 India market estimates and forecast 2017 - 2030 (USD Million)
Fig. 61 Australia
Fig. 62 Australia market estimates and forecast 2017 - 2030 (USD Million)
Fig. 63 South Korea
Fig. 64 South Korea market estimates and forecast 2017 - 2030 (USD Million)
Fig. 65 Singapore
Fig. 66 Singapore market estimates and forecast 2017 - 2030 (USD Million)
Fig. 67 Latin America
Fig. 68 Latin America market estimates and forecast 2017 - 2030 (USD Million)
Fig. 69 Brazil
Fig. 71 Brazil market estimates and forecast 2017 - 2030 (USD Million)
Fig. 72 Mexico
Fig. 73 Mexico market estimates and forecast 2017 - 2030 (USD Million)
Fig. 74 Argentina
Fig. 75 Argentina market estimates and forecast 2017 - 2030 (USD Million)
Fig. 76 Middle East & Africa
Fig. 77 Middle East and Africa market estimates and forecast 2017 - 2030 (USD Million)
Fig. 78 South Africa
Fig. 79 South Africa market estimates and forecast 2017 - 2030 (USD Million)
Fig. 80 Saudi Arabia
Fig. 81 Saudi Arabia market estimates and forecast 2017 - 2030 (USD Million)
Fig. 82 UAE
Fig. 83 UAEmarket estimates and forecast 2017 - 2030 (USD Million)
Fig. 84 Company market share analysis
Fig. 85 Company market position analysis (Revenue US$ mn)
Fig. 86 Company market position analysis (Profit Margin)
Fig. 87 Competitive dashboard analysis
Fig. 88 Regional Network Map
Fig. 1 Antibody-drug conjugates market segmentation
Fig. 2 Market research process
Fig. 3 Data triangulation techniques
Fig. 4 Primary research pattern
Fig. 5 Market research approaches
Fig. 6 Value-chain-based sizing & forecasting
Fig. 7 QFD modeling for market share assessment
Fig. 8 Market formulation & validation
Fig. 9 Antibody-drug conjugates market snapshot
Fig. 10 Antibody-drug conjugates market driver impact
Fig. 11 Global population by age group, 2016, 2020, & 2027
Fig. 12 Global cancer cases projection,2020 - 2030 (Number of new registered cases)
Fig. 13 Antibody-drug conjugates market restraint impact
Fig. 14 Penetration and growth prospect mapping
Fig. 15 SWOT analysis, by factor (political & legal economic and technological)
Fig. 16 Porter’s five forces analysis
Fig. 17 Antibody-drug conjugates market: Application outlook and key takeaways
Fig. 18 Antibody-drug conjugates market: Application movement analysis
Fig. 19 Blood cancer market estimates and forecasts, 2017 - 2030
Fig. 20 Leukemia market estimates and forecasts, 2017 - 2030
Fig. 21 Multiple Myeloma market estimates and forecasts, 2017 - 2030
Fig. 22 Lymphoma market estimates and forecasts, 2017 - 2030
Fig. 23 Breast cancer market estimates and forecasts, 2017 - 2030
Fig. 24 Urothelial cancer market estimates and forecasts, 2017 - 2030
Fig. 25 Others market estimates and forecasts, 2017 - 2030
Fig. 26 Antibody-drug conjugates market: Technology outlook and key takeaways
Fig. 27 Antibody-drug conjugates market: Technology movement analysis
Fig. 28 Cleavable linker market estimates and forecasts, 2017 - 2030
Fig. 29 Non-cleavable linker market estimates and forecasts, 2017 - 2030
Fig. 30 Linkerless market estimates and forecasts, 2017 - 2030
Fig. 31 Antibody-drug conjugates market: Regional outlook and key takeaways
Fig. 32 Antibody-drug conjugates market: Regional movement analysis
Fig. 33 North America
Fig. 34 North America market estimates and forecast 2017 - 2030 (USD Million)
Fig. 35 U.S.
Fig. 36 U.S. market estimates and forecast 2017 - 2030 (USD Million)
Fig. 37 Canada
Fig. 38 Canada market estimates and forecast 2017 - 2030 (USD Million)
Fig. 39 Europe
Fig. 40 Europe market estimates and forecast 2017 - 2030 (USD Million)
Fig. 41 UK
Fig. 42 UK market estimates and forecast 2017 - 2030 (USD Million)
Fig. 43 Germany
Fig. 44 Germany market estimates and forecast 2017 - 2030 (USD Million)
Fig. 45 Italy
Fig. 46 Italy market estimates and forecast 2017 - 2030 (USD Million)
Fig. 47 Spain
Fig. 48 Spain market estimates and forecast 2017 - 2030 (USD Million)
Fig. 49 Russia
Fig. 50 Russia market estimates and forecast 2017 - 2030 (USD Million)
Fig. 51 France
Fig. 52 France market estimates and forecast 2017 - 2030 (USD Million)
Fig. 53 Asia Pacific
Fig. 54 Asia Pacific market estimates and forecast 2017 - 2030 (USD Million)
Fig. 55 Japan
Fig. 56 Japan market estimates and forecast 2017 - 2030 (USD Million)
Fig. 57 China
Fig. 58 China market estimates and forecast 2017 - 2030 (USD Million)
Fig. 59 India
Fig. 60 India market estimates and forecast 2017 - 2030 (USD Million)
Fig. 61 Australia
Fig. 62 Australia market estimates and forecast 2017 - 2030 (USD Million)
Fig. 63 South Korea
Fig. 64 South Korea market estimates and forecast 2017 - 2030 (USD Million)
Fig. 65 Singapore
Fig. 66 Singapore market estimates and forecast 2017 - 2030 (USD Million)
Fig. 67 Latin America
Fig. 68 Latin America market estimates and forecast 2017 - 2030 (USD Million)
Fig. 69 Brazil
Fig. 71 Brazil market estimates and forecast 2017 - 2030 (USD Million)
Fig. 72 Mexico
Fig. 73 Mexico market estimates and forecast 2017 - 2030 (USD Million)
Fig. 74 Argentina
Fig. 75 Argentina market estimates and forecast 2017 - 2030 (USD Million)
Fig. 76 Middle East & Africa
Fig. 77 Middle East and Africa market estimates and forecast 2017 - 2030 (USD Million)
Fig. 78 South Africa
Fig. 79 South Africa market estimates and forecast 2017 - 2030 (USD Million)
Fig. 80 Saudi Arabia
Fig. 81 Saudi Arabia market estimates and forecast 2017 - 2030 (USD Million)
Fig. 82 UAE
Fig. 83 UAEmarket estimates and forecast 2017 - 2030 (USD Million)
Fig. 84 Company market share analysis
Fig. 85 Company market position analysis (Revenue US$ mn)
Fig. 86 Company market position analysis (Profit Margin)
Fig. 87 Competitive dashboard analysis
Fig. 88 Regional Network Map
